A new report has found that emerging companies, most with no presence in Australia, are responsible for over 90 per cent of gene, cell and nucleotide therapies currently in late-stage pipelines. …
Latest Video
New Stories
-
The 'post-rebate' era has started with or without supply chain reform
August 23, 2019 - - Latest News -
Is there even a plan for emerging therapies in Australia?
August 23, 2019 - - Latest News -
Federal government still finalising CAR-T agreement with Peter Mac
August 23, 2019 - - Latest News -
EBOS looking to 'the next wave of growth'
August 23, 2019 - - Latest News -
Bayer makes another move into cell therapy
August 22, 2019 - - Latest News -
Government could come for more given savings shortfall
August 22, 2019 - - Latest News -
Patients might be hoping their medicine belongs to a large company
August 22, 2019 - - Latest News